Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 20/20 | 1.00 |
| ▸ | NSD2 | O96028 | 1/20 | 0.75 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.75 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.75 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.75 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.75 |
| ▸ | BID | P55957 | 1/20 | 0.75 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.75 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.75 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.75 |
| ▸ | ASPH | Q12797 | 1/20 | 0.75 |
| ▸ | BCL2L2 | Q92843 | 1/20 | 0.75 |
| ▸ | BAD | Q92934 | 1/20 | 0.75 |
| ▸ | NSD1 | Q96L73 | 1/20 | 0.75 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19839471 | 1.00 | BCL2 (1.00) | BCL2NSD2ADORA3CYP2C9ADRA2C | |
| SCHEMBL19503528 | 0.94 | BCL2 (0.89) | BCL2NSD2ADORA3CYP2C9ADRA2C | |
| SCHEMBL20580491 | 0.93 | BCL2 (1.00) | BCL2 | |
| SCHEMBL22858622 | 0.93 | BCL2 (0.86) | BCL2 | |
| SCHEMBL29376921 | 0.93 | BCL2 (1.00) | BCL2 | |
| SCHEMBL21480823 | 0.92 | BCL2 (0.85) | BCL2 | |
| SCHEMBL21480818 | 0.92 | BCL2 (0.85) | BCL2 | |
| SCHEMBL25481750 | 0.92 | BCL2 (0.85) | BCL2BCL2L1MCL1BCL2L2 | |
| SCHEMBL22858621 | 0.92 | BCL2 (0.85) | BCL2 | |
| SCHEMBL20580899 | 0.92 | BCL2 (0.88) | BCL2NSD2ADORA3CYP2C9ADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240316069-A1 | METHODS OF TREATING MULTIPLE SCLEROSIS | ASCENTAGE PHARMA GROUP CORP LIMITED (CN) | 2024-09-26 | — | — | US | claimed |
| US-20260053815-A1 | COMBINATION PRODUCT OF A BCL-2/BCL-XL INHIBITOR AND A CHEMOTHERAPEUTIC AGENT AND USE THEREOF IN THE PREVENTION AND/OR TREATMENT OF DISEASES | ASCENTAGE PHARMA GROUP CORP LIMITED (CN) | 2026-02-26 | — | — | US | disclosed |
| US-12370197-B2 | Combination product of a Bcl-2/Bcl-xL inhibitor and a chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2025-07-29 | — | — | US | disclosed |
| US-20250152580-A1 | METHODS FOR TREATING IMMUNE DISEASES | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2025-05-15 | — | — | US | disclosed |
| US-20240316069-A1 | METHODS OF TREATING MULTIPLE SCLEROSIS | ASCENTAGE PHARMA GROUP CORP LIMITED (CN) | 2024-09-26 | — | — | US | disclosed |
| US-20230398110-A1 | COMPOSITIONS AND METHODS FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2023-12-14 | — | — | US | disclosed |
| US-20230301989-A1 | COMPOSITIONS AND METHODS FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2023-09-28 | — | — | US | disclosed |
| US-11718613-B2 | N-(phenylsulfonyl)benzamides and related compounds as Bcl-2 inhibitors | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2023-08-08 | — | — | US | disclosed |
| EP-4129999-A1 | N-(PHENYLSULFONYL)BENZAMIDES AND RELATED COMPOUNDS AS BCL-2 INHIBITORS | The Regents Of The University Of Michigan (US) | 2023-02-08 | — | — | EP | disclosed |
| US-11554127-B2 | Synergistic antitumor effect of Bcl-2 inhibitor combined with rituximab and/or bendamustine or Bcl-2 inhibitor combined with CHOP | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2023-01-17 | — | — | US | disclosed |
| US-11491167-B2 | Combination product of Bcl-2 inhibitor and chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2022-11-08 | — | — | US | disclosed |
| US-11478469-B2 | Combination product of BCL-2 inhibitor and MDM2 inhibitor and use thereof in the prevention and/or treatment of diseases | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2022-10-25 | — | — | US | disclosed |
| US-11478470-B2 | Combination product of Bcl-2 inhibitor or Bcl-2/Bcl-xL dual inhibitor and BTK inhibitor and use thereof in the prevention and/or treatment of diseases | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2022-10-25 | — | — | US | disclosed |
| US-20220143039-A1 | COMBINATION PRODUCT OF A BCL-2/BCL-XL INHIBITOR AND A CHEMOTHERAPEUTIC AGENT AND USE THEREOF IN THE PREVENTION AND/OR TREATMENT OF DISEASES | ASCENTAGE PHARMA GROUP CORP LIMITED (CN) | 2022-05-12 | — | — | US | disclosed |
| US-20220031694-A1 | COMBINATION PRODUCT OF BCL-2 INHIBITOR AND MDM2 INHIBITOR AND USE THEREOF IN THE PREVENTION AND/OR TREATMENT OF DISEASES | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2022-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11554127-B2 | Synergistic antitumor effect of Bcl-2 inhibitor combined with rituximab and/or bendamustine or Bcl-2 inhibitor combined with CHOP | BCL2, BAK1, BCL3 | BCL2 1/4885NSD2 1816/4885ADORA3 4423/4885 |
| US-20230301989-A1 | COMPOSITIONS AND METHODS FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS | SSB, BCL3, BCL6 | BCL2 8/4885NSD2 2490/4885ADORA3 4567/4885 |
| US-20230398110-A1 | COMPOSITIONS AND METHODS FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS | FABP1, LIPC, PNLIP | BCL2 43/4885NSD2 3464/4885ADORA3 4530/4885 |
| US-20250152580-A1 | METHODS FOR TREATING IMMUNE DISEASES | HLA-DRB1, SSB, NFATC1 | BCL2 2418/4885NSD2 4165/4885ADORA3 1652/4885 |
| US-20220143039-A1 | COMBINATION PRODUCT OF A BCL-2/BCL-XL INHIBITOR AND A CHEMOTHERAPEUTIC AGENT AND USE THEREOF IN THE PREVENTION AND/OR TREATMENT OF DISEASES | BCL2, BCL3, BCL2L13 | BCL2 1/4885NSD2 1605/4885ADORA3 3659/4885 |
| US-11491167-B2 | Combination product of Bcl-2 inhibitor and chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases | BCL2, BCL2L1, BCL2L2 | BCL2 1/4885NSD2 2114/4885ADORA3 4642/4885 |
| US-12370197-B2 | Combination product of a Bcl-2/Bcl-xL inhibitor and a chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases | BCL2, BCL3, BCL2L13 | BCL2 1/4885NSD2 1605/4885ADORA3 3659/4885 |
| US-11718613-B2 | N-(phenylsulfonyl)benzamides and related compounds as Bcl-2 inhibitors | BCL2A1, BCL3, BCL2 | BCL2 3/4885NSD2 214/4885ADORA3 2822/4885 |
| US-11478470-B2 | Combination product of Bcl-2 inhibitor or Bcl-2/Bcl-xL dual inhibitor and BTK inhibitor and use thereof in the prevention and/or treatment of diseases | BCL2L1, BAK1, BCL2A1 | BCL2 5/4885NSD2 1499/4885ADORA3 4823/4885 |
| US-20240316069-A1 | METHODS OF TREATING MULTIPLE SCLEROSIS | PMP22, AQP4, NEFM | BCL2 2323/4885NSD2 2484/4885ADORA3 2224/4885 |
| US-20220031694-A1 | COMBINATION PRODUCT OF BCL-2 INHIBITOR AND MDM2 INHIBITOR AND USE THEREOF IN THE PREVENTION AND/OR TREATMENT OF DISEASES | BCL2, BCL2L2, BCL2L1 | BCL2 1/4885NSD2 749/4885ADORA3 4803/4885 |
| US-20260053815-A1 | COMBINATION PRODUCT OF A BCL-2/BCL-XL INHIBITOR AND A CHEMOTHERAPEUTIC AGENT AND USE THEREOF IN THE PREVENTION AND/OR TREATMENT OF DISEASES | BCL3, BCL2, BCL2L1 | BCL2 2/4885NSD2 988/4885ADORA3 3308/4885 |
| US-11478469-B2 | Combination product of BCL-2 inhibitor and MDM2 inhibitor and use thereof in the prevention and/or treatment of diseases | BCL2, BCL2L2, BCL2L1 | BCL2 1/4885NSD2 749/4885ADORA3 4803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.